Table of Contents Author Guidelines Submit a Manuscript
Prostate Cancer
Volume 2017, Article ID 5687212, 7 pages
https://doi.org/10.1155/2017/5687212
Research Article

Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus

1Department of Biochemistry, Owaisi Group of Hospitals, DCMS, Hyderabad, Telangana, India
2Department of Urology, Owaisi Group of Hospitals, DCMS, Hyderabad, Telangana, India
3Salar-e-Millat Research Centre, PEH, DCMS, Hyderabad, Telangana, India

Correspondence should be addressed to Mohammed Abdul Majid Adil; ni.oc.oohay@lidamamrd

Received 17 May 2016; Revised 24 August 2016; Accepted 25 October 2016; Published 12 January 2017

Academic Editor: Weide Zhong

Copyright © 2017 Shahana Sarwar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Christudoss, R. Selvakumar, J. J. Fleming, and G. Gopalakrishnan, “Zinc status of patients with benign prostatic hyperplasia and prostate carcinoma,” Indian Journal of Urology, vol. 27, no. 1, pp. 14–18, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Bracarda, O. De Cobelli, C. Greco et al., “Cancer of the prostate,” Critical Reviews in Oncology/Hematology, vol. 56, no. 3, pp. 379–396, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. J. E. McNeal, “Regional morphology and pathology of the prostate,” American Journal of Clinical Pathology, vol. 49, no. 3, pp. 347–357, 1968. View at Publisher · View at Google Scholar · View at Scopus
  4. W. J. Catalona, A. W. Partin, K. M. Slawin et al., “Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial,” The Journal of the American Medical Association, vol. 279, no. 19, pp. 1542–1547, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. J. M. Young, D. J. Muscatello, and J. E. Ward, “Are men with lower urinary tract symptoms at increased risk of prostate cancer? A systematic review and critique of the available evidence,” BJU International, vol. 85, no. 9, pp. 1037–1048, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. C. T. Brown, E. O'Flynn, J. Van Der Meulen, S. Newman, A. R. Mundy, and M. Emberton, “The fear of prostate cancer in men with lower urinary tract symptoms: should symptomatic men be screened?” BJU International, vol. 91, no. 1, pp. 30–32, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. D. F. Gleason and G. T. Mellinger, “Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging,” The Journal of Urology, vol. 111, no. 1, pp. 58–64, 1974. View at Publisher · View at Google Scholar · View at Scopus
  8. N. A. Romas, “Prostatic acid phosphatase: current concepts,” Seminars in urology, vol. 1, no. 3, pp. 177–185, 1983. View at Google Scholar · View at Scopus
  9. S. C. Kukreja, A. Shanmugam, and T. E. Lad, “Hypocalcemia in patients with prostate cancer,” Calcified Tissue International, vol. 43, no. 6, pp. 340–345, 1988. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Kapur, “Phosphorus balance and prostate cancer,” Indian Journal of Experimental Biology, vol. 37, no. 7, pp. 623–626, 1999. View at Google Scholar · View at Scopus
  11. E. Kesse, S. Bertrais, P. Astorg et al., “Dairy products, calcium and phosphorus intake, and the risk of prostate cancer: results of the French prospective SU.VI.MAX (Supplémentation en Vitamines et Minéraux Antioxydants) study,” British Journal of Nutrition, vol. 95, no. 3, pp. 539–545, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. K. M. Wilson, I. M. Shui, L. A. Mucci, and E. Giovannucci, “Calcium and phosphorus intake and prostate cancer risk: a 24-y follow-up study,” American Journal of Clinical Nutrition, vol. 101, no. 1, pp. 173–183, 2014. View at Publisher · View at Google Scholar
  13. L. I. Stowell, L. E. Sharman, and K. Hamel, “An enzyme-linked immunosorbent assay (ELISA) for prostate-specific antigen,” Forensic Science International, vol. 50, no. 1, pp. 125–138, 1991. View at Publisher · View at Google Scholar · View at Scopus
  14. A. B. Gutman and E. B. Gutman, “An 'ACID' phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland,” Journal of Clinical Investigation, vol. 17, no. 4, pp. 473–478, 1938. View at Publisher · View at Google Scholar
  15. H. J. Gitelman, “An improved automated procedure for the determination of calcium in biological specimens,” Analytical Biochemistry, vol. 18, no. 3, pp. 521–531, 1967. View at Publisher · View at Google Scholar · View at Scopus
  16. N. W. Teitz, Fundamentals of Clinical Chemistry, W.B. Saunders, Philadelphia, Pa, USA, 2nd edition, 1976.
  17. K. Jung, J. Reiche, A. Boehme et al., “Analysis of subforms of free prostate-specific antigen in serum by two-dimensional gel electrophoresis: potential to improve diagnosis of prostate cancer,” Clinical Chemistry, vol. 50, no. 12, pp. 2292–2301, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Anim, E. Kehinde, M. Sheikh et al., “Serum prostate-specific antigen levels in middle eastern men with subclinical prostatitis,” Medical Principles and Practice, vol. 16, no. 1, pp. 53–58, 2006. View at Publisher · View at Google Scholar
  19. A. Taira, G. Merrick, K. Wallner, and M. Dattoli, “Reviving the acid phosphatase test for prostate cancer,” Oncology, vol. 21, no. 8, pp. 1003–1010, 2007. View at Google Scholar · View at Scopus
  20. L. Nguyen, A. Chapdelaine, and S. Chevalier, “Prostatic acid phosphatase in serum of patients with prostatic cancer is a specific phosphotyrosine acid phosphatase,” Clinical Chemistry, vol. 36, no. 8, pp. 1450–1455, 1990. View at Google Scholar · View at Scopus
  21. T. A. Stamey, N. Yang, and A. R. Hay, “Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate,” New England Journal of Medicine, vol. 317, no. 15, pp. 909–916, 1987. View at Publisher · View at Google Scholar · View at Scopus
  22. Ö. Yaman, Ç. Göğüş, Ö. Tulunay, Z. Tokatli, and E. Özden, “Increased prostate-specific antigen in subclinical prostatitis: the role of aggressiveness and extension of inflammation,” Urologia Internationalis, vol. 71, no. 2, pp. 160–164, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. L. H. Simardi, M. Tobias-Machado, G. T. Kappaz, P. Taschner Goldenstein, J. M. Potts, and E. R. Wroclawski, “Influence of asymptomatic histologic prostatitis on serum prostate-specific antigen: a prospective study,” Urology, vol. 64, no. 6, pp. 1098–1101, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Raskin, C. J. McClain, and T. A. Medsger Jr., “Hypocalcemia associated with metastatic bone disease. A retrospective study,” Archives of Internal Medicine, vol. 132, no. 4, pp. 539–543, 1973. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Szentirmai, C. Constantinou, J. M. Rainey, and J. E. Loewenstein, “Hypocalcemia due to avid calcium uptake by osteoblastic metastases of prostate cancer,” Western Journal of Medicine, vol. 163, no. 6, pp. 577–578, 1995. View at Google Scholar · View at Scopus
  26. G. D. Ludwig, “Hypocalcemia and hypophosphatemia accompanying osteoblastic osseous metastases: studies of calcium and phosphate metabolism and parathyroid function,” Annals of Internal Medicine, vol. 56, no. 4, pp. 676–677, 1962. View at Publisher · View at Google Scholar
  27. H. G. Skinner and G. G. Schwartz, “Serum calcium and incident and fatal prostate cancer in the national health and nutrition examination survey,” Cancer Epidemiology, Biomarkers & Prevention, vol. 17, no. 9, pp. 2302–2305, 2008. View at Publisher · View at Google Scholar · View at Scopus